A German cannabis physician, a nurse and a pharmacist walk into a bar...I mean a podcast. In this fascinating episode of Reefer MEDness, Trevor (pharmacist) and Kirk (registered nurse) sit down with Dr. Vlad Gavril, a German GP specializing in cannabinoid therapy, to explore how medical cannabis is transforming patient care in Germany.

Dr. Vlad explains how Germany’s partial cannabis legalization in April 2024 dramatically changed access to medical cannabis. But with this rapid expansion comes challenges: inconsistent patient education, and stigma around cannabis.

The conversation unpacks how Dr. Vlad uses cannabis clinically—from chronic pain and insomnia to depression and ADHD—and why education about cannabinoids, terpenes, and individualized treatment is critical. Dr. Vlad shares how he guides patients toward vaporization rather than smoking, explores terpene-based strain selection, and explains the importance of activating the body’s endocannabinoid system through lifestyle changes alongside cannabis therapy.

This episode offers rare insight into the rapidly evolving global landscape of medical cannabis policy, patient care, and cannabinoid science.

Listen now to learn how cannabis medicine is being practiced in Germany—and what Canadian clinicians and patients can learn from it.

Can a massive data project finally answer the biggest questions about medical cannabis?

In Part 2 of our conversation with Dr. Johannes Thrul, we explore the National Cannabis Study, an ambitious effort to build a global repository of cannabis research and real-world patient data. From standardized tools like the Cannabis Use Questionnaire to combining datasets from multiple studies, this project aims to uncover how cannabis truly impacts conditions like chronic pain, anxiety, PTSD, and insomnia.

With AI analysis, collaborative research, and a goal of 10,000 participants, the team hopes to transform fragmented cannabis studies into one powerful evidence base.

Listen now to learn how this groundbreaking cannabis database could reshape the future of cannabis medicine.

Johannes Thrul - LinkedIn

Cannabis & Health Research Initiative - website

Transcripts, papers and so much more at: reefermed.ca

What truth can big data unlock about medical cannabis?

Dr. Johannes Thrul from Johns Hopkins talks about cannabis use disorder, psychiatric risks, THC intoxication, and the groundbreaking Cannabis Health Research Initiative.

The ambitious Cannabis Health Research Initiative is a groundbreaking effort to build a national medical cannabis registry and research database. Dr. Thrul shares how the National Cannabis Study will track new medical cannabis users over time, analyze biomarkers and electronic health records, and use AI to identify if medicinal cannabis is helping or not. The goal: generate real-world evidence about the benefits, risks, and clinical applications of cannabinoids—helping researchers design better clinical trials and improve patient care.

Listen now to learn how real-world data may reshape the science of cannabis medicine.

Johannes Thrul - LinkedIn

Cannabis & Health Research Initiative - website

Transcripts, papers and so much more at: reefermed.ca

What will it take for cannabis and natural compounds to truly enter the mainstream—from toothpaste to energy drinks?

In Part 2 of Trevor and Kirk’s conversation with biotech financier and cannabis strategist David Traylor, they discuss how major corporations might explore integrating cannabinoids like CBN and CBD and other natural products into everyday consumer products.

David explains how his Skunk Works Nature AI advisory group connects global companies with world-class experts in pharmacology, biotechnology, and regulatory strategy to develop cannabinoid and other natural product based innovations. From potential sleep-supporting CBN toothpaste, to the role of pharmacogenomics and personalized medicine, this episode explores how science, investment, and product development intersect in the cannabis, psychedelic and natural product sectors.

Trevor and Kirk also unpack the broader forces shaping the cannabis industry—stigma, regulatory barriers, banking challenges, and the tension between single-molecule pharmaceutical approaches vs. whole-plant medicine. Could big brands like PepsiCo or Red Bull be the catalyst that finally normalizes cannabinoid ingredients in consumer products? And what role does fear, policy, and economics play in slowing cannabis acceptance?

Listen now to learn how cannabis science, biotech innovation, and big-industry investment could reshape the future of medicine, consumer products, and natural compounds.

David Traylor - LinkedIn

Skunk Works Nature AI - website

Transcripts, papers and so much more at: reefermed.ca

Can big brands explore cannabis, & psychedelics without saying it out loud?

What happens when cannabis and natural compounds expertise, a global network, and AI-driven product strategy collide? David Traylor of Golden Eagle Partners introduces Skunk Works Nature AI. This new venture helps major consumer brands quietly explore cannabinoids and other natural compounds. Does a large beverage company want a CBG infused drink to help University Students get over their exam anxiety? Does a Fast-Moving Consumer Goods Brand want a toothpaste with CBN to help people sleep? Does a cosmetics company want a micro-dosed psychedelic lipstick for when an artist or CEO needs some creativity on demand? Large companies may be canna-curious but stigma still slows innovation. The confidential advice and expertise of Skunk Works Nature AI should bring serious players into the space. The future belongs to evidence-based product development built around cannabinoids, alkaloids, terpenes, and other natural compounds.

David also discusses the capital crunch in cannabis, why so many firms have exited the sector, and a fascinating discussion about cannabis language and policy, including David’s clearer framework of THC-plus and THC-minus.

Listen now to learn how investors, scientists, and global brands are preparing for the next phase of cannabis, psychedelics, and functional natural products.

David Traylor - LinkedIn

Skunk Works Nature AI - website

Transcripts, papers and so much more at: reefermed.ca

What if the fastest way to feel cannabis effects isn’t through your lungs… but through your nose?

Trevor and Kirk explore the science behind a unique cannabis accessory: the Nozzr, a nasal inhalation device designed to deliver vaporized cannabis through the nose rather than the mouth.

Inventor and respiratory therapist Yvette Webb shares how the idea emerged during the COVID-19 pandemic while researching terpene interactions with respiratory viruses. Drawing on respiratory therapy, aerosol physics, and cannabis pharmacology, she explains how nasal inhalation may deliver cannabinoids and terpenes faster, potentially improving onset time, reducing coughing, and enhancing terpene perception through the olfactory system.

Trevor and Kirk discuss whether nasal inhalation could offer benefits for medical cannabis patients, including people with chronic pain, migraines, spasticity, or mobility challenges.

Is nasal cannabis inhalation the next evolution in cannabis consumption—or just a fascinating experiment in delivery science?

Listen now to learn how terpene science, respiratory therapy, and cannabis innovation collide in this unusual but thought-provoking conversation.

Yvette Web - LinkedIn

Nozzr - Instagram

Cream of the Crop - website

Transcripts, papers and so much more at: reefermed.ca

What are future pharmacists really being taught about cannabis—and is the stigma finally disappearing?

In this episode of Reefer MEDness, Trevor and Kirk sit down with a University of Manitoba pharmacy student Ariana to explore how cannabis is being taught in modern healthcare education. From cannabinoid receptors (CB1/CB2) to drug interactions via CYP3A4, this conversation breaks down how cannabis is shifting from stigma to legitimate therapy.

You’ll learn about routes of administration, medical uses like pain and chemotherapy-induced nausea, and why healthcare providers must consider cannabis in patient care. Perhaps most importantly, Ariana provides insight into a cultural shift: cannabis is no longer viewed solely as a “drug of abuse,” but is starting to be seen as a legitimate therapeutic option within healthcare education.

Listen now to learn how cannabis education is reshaping pharmacy, patient care, and clinical decision-making.

College of Pharmacy - University of Manitoba - Website

Transcripts, papers and so much more at: reefermed.ca